A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.

Autor: Glauß S; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany., Neumeyer V; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany., Hanesch L; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany., Marek J; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany., Hartmann N; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany., Wiedemann GM; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany., Altomonte J; Department of Internal Medicine II, Rechts der Isar Hospital, Technical University of Munich, 81675 Munich, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2024 Oct 06; Vol. 16 (19). Date of Electronic Publication: 2024 Oct 06.

Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.

Autor: Göbel S; Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany., Jaén KE; Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.; Department of Internal Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munchen, Germany., Dorn M; Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.; Faculty of Process and Systems Engineering, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany., Neumeyer V; Department of Internal Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munchen, Germany., Jordan I; ProBioGen AG, Berlin, Germany., Sandig V; ProBioGen AG, Berlin, Germany., Reichl U; Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.; Chair for Bioprocess Engineering, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany., Altomonte J; Department of Internal Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munchen, Germany., Genzel Y; Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.

Publikováno v: Biotechnology and bioengineering [Biotechnol Bioeng] 2023 Sep; Vol. 120 (9), pp. 2639-2657. Date of Electronic Publication: 2023 Feb 21.

Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures.

Autor: Göbel S; Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Sandtorstr. 1, 39106, Magdeburg, Germany., Kortum F; Department of Internal Medicine II, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany., Chavez KJ; Department of Internal Medicine II, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany., Jordan I; ProBioGen AG, Herbert-Bayer-Str. 8, 13086, Berlin, Germany., Sandig V; ProBioGen AG, Herbert-Bayer-Str. 8, 13086, Berlin, Germany., Reichl U; Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Sandtorstr. 1, 39106, Magdeburg, Germany.; Chair for Bioprocess Engineering, Otto-Von-Guericke-University Magdeburg, Universitätsplatz 2, 39106, Magdeburg, Germany., Altomonte J; Department of Internal Medicine II, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany., Genzel Y; Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Sandtorstr. 1, 39106, Magdeburg, Germany. genzel@mpi-magdeburg.mpg.de.

Publikováno v: Applied microbiology and biotechnology [Appl Microbiol Biotechnol] 2022 Aug; Vol. 106 (13-16), pp. 4945-4961. Date of Electronic Publication: 2022 Jun 29.

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.

Autor: Marek J; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany., Hanesch L; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany., Krabbe T; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany., El Khawanky N; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany., Heidegger S; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany., Altomonte J; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Aug 05; Vol. 30, pp. 117-131. Date of Electronic Publication: 2023 Aug 05 (Print Publication: 2023).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.